Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer
Mandate

Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer

October 27, 2016

Vinge has advised D. Carnegie & Co AB (publ) (“D. Carnegie & Co”) in connection with a mandatory offer to the shareholders and warrant holders of D. Carnegie & Co, made by Blackstone through Vega Holdco S.à r.l. (”Vega Holdco”). Vega Holdco offers SEK 100 in cash per A- and B-share in D. Carnegie & Co. Based on all outstanding shares and warrants in the company, the total value of D. Carnegie & Co amounts to approximately SEK 7.8 billion.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson and Sofie Bjärtun.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026